Entrada Therapeutics, Inc.

TRDA · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income$66-$7-$95-$51
Dep. & Amort.$4$3$2$1
Deferred Tax$0$0$0$0
Stock-Based Comp.$18$13$0$3
Change in WC-$119$136-$11-$3
Other Non-Cash-$10-$6$10$0
Operating Cash Flow-$42$140-$94-$51
Investing Activities
PP&E Inv.-$3-$6-$3-$5
Net Acquisitions$0$0$0$0
Inv. Purchases-$438-$407-$222$0
Inv. Sales/Matur.$413$274$76$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$28-$138-$149-$5
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$100$19$0$191
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$3$2$0$117
Financing Cash Flow$103$21$0$307
Forex Effect$0$0-$4$0
Net Chg. in Cash$34$22-$246$252
Supplemental Information
Beg. Cash$72$49$291$39
End Cash$105$72$45$291
Free Cash Flow-$45$134-$97-$55
Entrada Therapeutics, Inc. (TRDA) Financial Statements & Key Stats | AlphaPilot